NSE - Delayed Quote INR

Bliss GVS Pharma Limited (BLISSGVS.NS)

Compare
160.75
-6.20
(-3.71%)
At close: January 10 at 3:30:02 PM GMT+5:30
Loading Chart for BLISSGVS.NS
DELL
  • Previous Close 166.95
  • Open 167.44
  • Bid --
  • Ask --
  • Day's Range 159.01 - 168.44
  • 52 Week Range 92.15 - 185.50
  • Volume 702,337
  • Avg. Volume 1,432,798
  • Market Cap (intraday) 16.941B
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) 27.02
  • EPS (TTM) 5.95
  • Earnings Date Jan 21, 2025 - Jan 25, 2025
  • Forward Dividend & Yield 0.50 (0.31%)
  • Ex-Dividend Date Jul 19, 2024
  • 1y Target Est --

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, soaps, sprays, and vaginal washes. In addition, the company offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

www.blissgvs.com

831

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BLISSGVS.NS

View More

Performance Overview: BLISSGVS.NS

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BLISSGVS.NS
1.57%
S&P BSE SENSEX
1.11%

1-Year Return

BLISSGVS.NS
26.63%
S&P BSE SENSEX
8.39%

3-Year Return

BLISSGVS.NS
64.26%
S&P BSE SENSEX
29.52%

5-Year Return

BLISSGVS.NS
11.57%
S&P BSE SENSEX
86.67%

Compare To: BLISSGVS.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BLISSGVS.NS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    16.91B

  • Enterprise Value

    15.52B

  • Trailing P/E

    26.92

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.14

  • Price/Book (mrq)

    1.67

  • Enterprise Value/Revenue

    1.95

  • Enterprise Value/EBITDA

    11.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.93%

  • Return on Assets (ttm)

    6.06%

  • Return on Equity (ttm)

    7.16%

  • Revenue (ttm)

    8B

  • Net Income Avi to Common (ttm)

    634.2M

  • Diluted EPS (ttm)

    5.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.2B

  • Total Debt/Equity (mrq)

    8.99%

  • Levered Free Cash Flow (ttm)

    137.17M

Research Analysis: BLISSGVS.NS

View More

People Also Watch